ALKS (alkermes.com) Market Value to Book Value Ratio

Official company branding of Alkermes PLC (ALKS)

This price chart for Alkermes plc (ALKS) illustrates valuation trends, reflecting the impact of patent disputes and payment volatility, with the key metric currently at 4.15. Alkermes plc (ALKS) develops mental health treatments, leveraging unique long-acting injection methods and strict FDA oversight. Management has effectively optimized the asset structure, focusing on intellectual property protection and specialized innovations.

ALKS Alkermes Corp: Market Value to Book Value in the range 07/04/2022 - 10/27/2026

Financial and market metric breakdowns for Alkermes PLC (ALKS)

- price and consensus price forecast:
Price Chart Alkermes plc|ALKS - Analyst Median Target
- market capitalization data:
Market Value Alkermes Inc.|ALKS - Full Business Value
- book capitalization data:
Book Value per Share Alkermes|ALKS - Accounting Value of Company|Market Capitalization to Book Value Ratio alkermes.com|ALKS - Company Total Assets
- debt and liquidity data:
Debt to Equity Alkermes plc|ALKS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Alkermes Inc.|ALKS - Company Total Debt|Debts to Book Capitalization Alkermes Inc.
Initial company analysis:Alkermes plc - ALKS
Original product of Alkermes Inc.

For the biopharmaceutical Alkermes plc (ALKS), which invests in "green chemistry" to reduce production toxicity, this ratio reflects the market premium over the value of tangible and intangible assets. By analyzing the company's market-to-book ratio, an investor determines the extent to which quotes are inflated relative to equity, allowing for an assessment of the risk of overpayment at the current liquidity level.

Main competitors

Avadel Pharmaceuticals - Market Value to Book Value Ratio|ATAI (atai.life) - Market Capitalization to Book Value|Market Value to Book Value Ratio GH Research GHRS|Market Capitalization to Net Assets Mind Medicine (MindMed) Inc.|Compass Pathways (CMPS) - Market Capitalization to Book Value Ratio|Market Value to Book Value LB Corp (LBRX)|Market Capitalization to Book Value Ratio DRUG (Bright Minds Biosciences)|vandapharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Cybin Corp (CYBN)|ANRO: Market Value to Book Value|NRXP (NRx Pharma) - Market Value to Book Value Ratio|Cingulate (CING) - Market Cap to Net Assets Ratio|SILO (Silo Pharma) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio China Pharma (CPHI)|Clearmind Medicine Inc. (CMND) - Market Cap to Net Assets Ratio|Market Value to Book Value PBM (Psyence Biomedical Ltd)|Clearmind Medicine (SPRC) - Market Value to Book Value Ratio|Seelos Therapeutics Inc - Market Capitalization to Net Assets|Market Value to Book Value Ratio VRPX (Virpax)|karunatx.com (KRTX) - Market Capitalization to Book Value